-
公开(公告)号：US11236137B2
公开(公告)日：2022-02-01
申请号：US16456218
申请日：2019-06-28
发明人： Bruce Yong Ma , Yu Fan , Jun Wang , Anliang Wang
IPC分类号： C07K14/435 , A61K39/35 , C12N15/81
摘要： Provided are an optimized Der f2 gene, a recombinant Der f2 protein encoded thereby, a vector comprising said gene, and a Pichia pastoris strain. Also provided are an expression method, a purification method, and an application of the recombinant Der f2 protein.
-
公开(公告)号：US20180155425A1
公开(公告)日：2018-06-07
申请号：US15554476
申请日：2015-10-30
发明人： Yong MA , Peipei CAO , Anliang WANG
摘要： Described is a bispecific antibody, and a method for producing the bispecific antibody. The bispecific antibody can be used in the preparation of a drug for treating a tumor with high cell expression of CD26. The antibody specifically hinds to human CD26 and human CD3 at the same time.
-
3.发明申请公开(公告)号：US20190389918A1
公开(公告)日：2019-12-26
申请号：US16456218
申请日：2019-06-28
发明人： Bruce Yong Ma , Yu Fan , Jun Wang , Anliang Wang
IPC分类号： C07K14/435 , C12N15/81 , A61K39/35
摘要： Provided are an optimized Der f2 gene, a recombinant Der f2 protein encoded thereby, a vector comprising said gene, and a Pichia pastoris strain. Also provided are an expression method, a purification method, and an application of the recombinant Der f2 protein.
-
4.发明申请PEGYLATED TISSUE KALLIKREIN, AND PREPARATION METHOD THEREFOR AND USES THEREOF 审中-公开聚乙烯吡唑啉酮组合物及其制备方法及用途公开(公告)号：US20170049864A1
公开(公告)日：2017-02-23
申请号：US15109364
申请日：2014-01-09
发明人： Bruce Yong MA , Jun WANG , Jing QIU , Dinglong WU , Chunlin XU , Chen CHEN , Yaofang WANG
CPC分类号： A61K38/4853 , A61K47/60 , C12N9/6445 , C12Y304/21035
摘要： The present invention relates to polyethylene glycol (PEG) modified protein drugs, and a PEGylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in SEQ ID No. 1 or SEQ ID No. 2, and the tissue kallikrein may be natural or recombinant. The PEG has a molecular weight of 20 to 40 kDa, and is conjugated to the N-terminal primary amino of the tissue kallikrein. In addition to the advantages of significantly extended half-life, significantly reduced immunogenicity and stable and uniform structure, the biological activity of the PEGylated KLK1 provided in the present invention is improved to a higher extent, which is more significant in the treatment of cerebral apoplexy and diabetic nephropathy in particular.
摘要翻译： 本发明涉及聚乙二醇（PEG）改性蛋白质药物和聚乙二醇化组织激肽释放酶，其制备方法和用途被公开。 组织激肽释放酶具有SEQ ID No.1或SEQ ID No.2所示的序列，组织激肽释放酶可以是天然的或重组的。 PEG具有20至40kDa的分子量，并且与组织激肽释放酶的N-末端的初级氨基缀合。 除了显着延长半衰期，免疫原性显着降低和结构稳定均匀的优点外，本发明提供的聚乙二醇化KLK1的生物活性也提高到更高程度，这在治疗脑中风中更为显着 特别是糖尿病肾病。
-
5.发明申请NOVEL USE OF MULTI-ARM POLYETHYLENE GLYCOL MODIFIER AND APPLICATION OF MULTI-ARM POLYETHYLENE GLYCOL MODIFIER IN L-ASPARAGINASUM MODIFICATION 审中-公开多臂聚乙烯甘油改性剂的新用途及多糖聚乙二醇改性剂在L-阿魏酸改性中的应用公开(公告)号：US20170043028A1
公开(公告)日：2017-02-16
申请号：US15109304
申请日：2014-07-28
发明人： Bruce Yong MA , Jun WANG , Dinglong WU , Chunlin XU , Yaofang WANG
IPC分类号： A61K47/48 , A61K9/00 , A61K9/19 , C12N9/96 , C12N9/82 , C12N9/80 , C12N9/06 , C12N9/16 , A61K38/50 , A61K38/44
CPC分类号： A61K47/48215 , A61K9/0019 , A61K9/19 , A61K38/44 , A61K38/50 , A61K47/60 , C12N9/0016 , C12N9/16 , C12N9/80 , C12N9/82 , C12N9/96 , C12Y104/01002 , C12Y301/03001 , C12Y305/01001 , C12Y305/01005
摘要： Methods for use of a multi-arm polyethylene glycol (PEG) modifier in modification of asparaginase. The described multi-arm PEG modifier enhances the subunit interaction of a multimeric protein to maintain the multimeric protein in a polymerized form, thereby improving the stability of the multimeric protein, maintaining the bioactivity of the multimeric protein, and reducing the probability of exposure of the antigen binding site after depolymerization of the subunits, so as to reduce the immunogenicity.
摘要翻译： 多臂聚乙二醇（PEG）改性剂改性天冬酰胺酶的方法。 所描述的多臂PEG修饰物增强多聚体蛋白质的亚单位相互作用以维持聚合形式的多聚体蛋白质，从而改善多聚体蛋白质的稳定性，维持多聚体蛋白质的生物活性，并降低 抗原结合位点解体后的亚基，从而降低免疫原性。
-
公开(公告)号：US11319353B2
公开(公告)日：2022-05-03
申请号：US16474217
申请日：2017-12-28
发明人： Bruce Yong Ma , Yu Fan , Anliang Wang , Jun Wang
IPC分类号： C07K14/435 , A61P37/08 , A61K39/35 , C12N15/81
摘要： A DNA sequence encoding Der p2 protein having a particular base sequence is codon-optimized for the Pichia pastoris expression system, which is conducive to expressing Der p2 in Pichia pastoris. After gene optimization and adding an activating element to increase the expression of Der p2 in molecular level, it was found that Der p2 is expressed at a higher level as compared with the prior art and has biological activity similar to the natural protein.
-
公开(公告)号：US10975128B2
公开(公告)日：2021-04-13
申请号：US16456357
申请日：2019-06-28
发明人： Bruce Yong Ma , Yu Fan , Jun Wang , Anliang Wang
IPC分类号： C07K14/435 , A61K38/00
摘要： Provided are an optimized proDer f1 gene, a proDer f1 protein encoded thereby, a vector comprising said gene, and a Pichia pastoris strain. Also provided are an expression method and a purification method of the proDer f1 protein.
-
公开(公告)号：US10052368B2
公开(公告)日：2018-08-21
申请号：US15109364
申请日：2014-01-09
发明人： Bruce Yong Ma , Jun Wang , Jing Qiu , Dinglong Wu , Chunlin Xu , Chen Chen , Yaofang Wang
CPC分类号： A61K38/4853 , A61K47/60 , C12N9/6445 , C12Y304/21035
摘要： The present invention relates to polyethylene glycol (PEG) modified protein drugs, and a PEGylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in SEQ ID No. 1 or SEQ ID No. 2, and the tissue kallikrein may be natural or recombinant. The PEG has a molecular weight of 20 to 40 kDa, and is conjugated to the N-terminal primary amino of the tissue kallikrein. In addition to the advantages of significantly extended half-life, significantly reduced immunogenicity and stable and uniform structure, the biological activity of the PEGylated KLK1 provided in the present invention is improved to a higher extent, which is more significant in the treatment of cerebral apoplexy and diabetic nephropathy in particular.
-
公开(公告)号：US11359191B2
公开(公告)日：2022-06-14
申请号：US16474240
申请日：2017-12-28
发明人： Bruce Yong Ma , Yu Fan , Anliang Wang , Jun Wang
摘要： A DNA sequence encoding Der p1 protein having a particular base sequence is codon-optimized for the Pichia pastoris expression system, which is conducive to expressing Der p1 in Pichia pastoris. After gene optimization and adding an activating element to increase the expression of Der p1 in molecular level, it was found that Der p1 is expressed at a higher level as compared with the prior art and has biological activity similar to the natural protein.
-
10.发明授权公开(公告)号：US10752686B2
公开(公告)日：2020-08-25
申请号：US15554476
申请日：2015-10-30
发明人： Yong Ma , Peipei Cao , Anliang Wang
IPC分类号： A61K39/395 , C07K16/30 , C07K16/28 , C07K16/46 , A61P35/00
摘要： Described is a bispecific antibody, and a method for producing the bispecific antibody. The bispecific antibody can be used in the preparation of a drug for treating a tumor with high cell expression of CD26. The antibody specifically hinds to human CD26 and human CD3 at the same time.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.017 秒)
